Celebrex News and Research

RSS

Celecoxib is a non-steroidal anti-inflammatory drug (NSAID) used in the treatment of osteoarthritis, rheumatoid arthritis, acute pain, painful menstruation and menstrual symptoms, and to reduce numbers of colon and rectum polyps in patients with familial adenomatous polyposis. It is marketed by Pfizer. It has the brand name Celebrex and Celebra (in other countries) for arthritis and Onsenal for polyps. Celecoxib is available by prescription in capsule form.

TV advertising of prescription drugs may increase visits to doctor not actual sales

TV advertising of prescription drugs may be prompting more people to visit their doctors rather than substantially increasing sales of advertised drugs, according to research led by the Medical University of South Carolina (MUSC).

12 Sep 2006

Drug ads and their influence on patients and doctors

Television ads for prescription drugs are everywhere, enticing people to ask their doctors for this drug or that one, but the effect this type of ad has on American healthcare may be more complicated than simply inducing patients to choose one brand or the other, according to a team of researchers.

12 Sep 2006

Celebrex shown to reduce incidence of potentially pre-malignant colorectal polyps

An international team of scientists reports that a single 400-milligram daily dose of celecoxib, commonly called Celebrex. and manufactured by Pfizer, significantly reduced recurrence of adenomas, or pre-malignant colon tumors - within three years of previous adenoma removal.

30 Aug 2006

Safety of popular painkiller Tylenol questioned

According to a new study the popular painkiller Tylenol may not be as safe to take as previously thought.

5 Jul 2006

COX enzymes work together in ways that suggest new biological roles

COX enzymes - well-known for their contrasting role in cardiovascular biology - interact physically to form a previously unrecognized biochemical partnership and function in the development of blood vessels in a mouse model.

9 Jun 2006

Experimental treatment increases response rates in advanced lung cancer

An early phase study pairing an experimental targeted therapy with a common anti-inflammatory produced promising results in patients with advanced lung cancer, researchers at UCLA's Jonsson Cancer Center reported.

1 Jun 2006

COX-1 and COX-2 enzymes may be blocked by pain medications

COX-1 and COX-2 enzymes may be blocked by pain medications such as Advil and Vioxx in a more complex manner than was previously understood, a Queen's University study has found.

29 May 2006

Heart risks from Vioxx happen much earlier than believed

A new study led by Queen's University researcher Linda Livesque shows that heart attacks related to the use of Vioxx - a drug once popular for the treatment of pain and inflammation - can occur within the first two weeks of use.

3 May 2006

Alternative anti-inflammatory drugs promise less cardiovascular problems

New type of anti-inflammatory drugs may reduce COX-2 cardiovascular problems, says Queen's researcher

25 Apr 2006

Possible alternatives found for Vioxx and Celebrex

According to Canadian and American researchers they have identified one reason why drugs like Celebrex and Vioxx - once popular for the treatment of pain and inflammation - cause heart problems.

18 Apr 2006

Researchers clarify the mechanism by which drugs like Celebrex and Vioxx cause heart problems

Researchers at the University of Pennsylvania School of Medicine have clarified the mechanism by which drugs like Celebrex and Vioxx cause heart problems, in multiple animal models.

18 Apr 2006

Inflammation cuts both ways

Inflammation cuts both ways. When invaded by an infectious agent, for example, the body calls on the forces of inflammation to fight and defeat the intruder.

6 Apr 2006

Celebrex appears to prevent colon cancer

Researchers say they have found that high doses of the arthritis drug Celebrex reduced the number of pre-cancerous growths in the colon.

4 Apr 2006

Regular use of COX-2 inhibitors may reduce the risk of breast cancer

Results from a new, five-year study show that regular use of popular prescription pain relievers may reduce the risk of breast cancer by up to 71 percent and may offer similar benefit in the prevention of prostate, colon and lung cancers.

4 Apr 2006

Medicinal properties in mahogany bark may hold colon cancer cure

U of So. Carolina cancer researcher Dr. Michael Wargovich is studying whether medicinal properties in the bark of mahogany trees may hold clues to understanding colon cancer.

27 Mar 2006

Celebrex safe for osteoarthritis

According to a study by Stanford University School of Medicine, Celebrex causes fewer gastrointestinal complications than traditional nonsteroidal anti-inflammatory painkillers or NSAIDs in osteoarthritis patients and does not increase the risk of heart attacks.

1 Mar 2006

Drugs formerly contraindicated for inflammatory bowel disease prove beneficial for pain relief

According to two studies published in the American Gastroenterological Association (AGA) journal Clinical Gastroenterology and Hepatology, prescription painkillers are effective in easing the pain of patients with dormant inflammatory bowel disease (IBD) and are not likely to cause symptom flare-ups in IBD patients in remissions

12 Feb 2006